AE Wealth Management LLC purchased a new position in shares of GlycoMimetics, Inc. (NASDAQ:GLYC – Get Rating) during the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 26,898 shares of the biotechnology company’s stock, valued at approximately $82,000. Other hedge funds and other institutional investors have also recently made changes to their positions in the […]
StockNews.com initiated coverage on shares of GlycoMimetics (NASDAQ:GLYC – Get Rating) in a research report issued on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock. Separately, Zacks Investment Research upgraded GlycoMimetics from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a research […]
GlycoMimetics (NASDAQ:GLYC – Get Rating) and Nature’s Sunshine Products (NASDAQ:NATR – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability. Analyst Ratings This is a breakdown of recent ratings […]
Equities research analysts expect that GlycoMimetics, Inc. (NASDAQ:GLYC – Get Rating) will report ($0.31) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for GlycoMimetics’ earnings, with estimates ranging from ($0.32) to ($0.29). GlycoMimetics reported earnings of ($0.28) per share in the same quarter last year, which indicates […]